カテゴリ： Market Monitor Global, 世界, 医療/バイオ

多発性硬化症（MS）治療薬のグローバル市場展望 2023年-2029年：コパキソン（グラチラマー酢酸塩）、ノバントロン（ミトキサントロン）、ジレニア（フィンゴリモド、Fty720）、オーバジオ（テリフルノミド）、テクフィデラ（フマル酸ジメチル）、フィラテグラスト（Sb683699、T-0047）、シポニモド（Baf312）、その他

■ 英語タイトル：Multiple Sclerosis (MS) Drugs Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23JU5785）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23JU5785
■ 発行日：2023年6月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品＆医療
■ ページ数：112
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[多発性硬化症（MS）治療薬のグローバル市場展望 2023年-2029年：コパキソン（グラチラマー酢酸塩）、ノバントロン（ミトキサントロン）、ジレニア（フィンゴリモド、Fty720）、オーバジオ（テリフルノミド）、テクフィデラ（フマル酸ジメチル）、フィラテグラスト（Sb683699、T-0047）、シポニモド（Baf312）、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の多発性硬化症（MS）治療薬市場規模と予測を収録しています。・世界の多発性硬化症（MS）治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の多発性硬化症（MS）治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の多発性硬化症（MS）治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「コパキソン（グラチラマー酢酸塩）」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

多発性硬化症（MS）治療薬のグローバル主要企業は、Bayer AG、 Bayhill Therapeutics、 Biogen Idec、 Cinnagen、 Daiichi Sankyo、 Eli Lilly、 Fast Forward Llc、 Antisense Therapeutics、 Apitope、 Five Prime Therapeutics、 Genmab、 Artielle Immunotherapeutics、 Genzyme、 Glaxosmithkline、 Gw Pharmaceuticals、 Innate Immunotherapeuticsなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、多発性硬化症（MS）治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の多発性硬化症（MS）治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の多発性硬化症（MS）治療薬市場：タイプ別市場シェア、2022年
・コパキソン（グラチラマー酢酸塩）、ノバントロン（ミトキサントロン）、ジレニア（フィンゴリモド、Fty720）、オーバジオ（テリフルノミド）、テクフィデラ（フマル酸ジメチル）、フィラテグラスト（Sb683699、T-0047）、シポニモド（Baf312）、その他

世界の多発性硬化症（MS）治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の多発性硬化症（MS）治療薬市場：用途別市場シェア、2022年
・RRMS、SPMS、PPMS、PRMS

世界の多発性硬化症（MS）治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の多発性硬化症（MS）治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における多発性硬化症（MS）治療薬のグローバル売上、2018年-2023年
・主要企業における多発性硬化症（MS）治療薬のグローバル売上シェア、2022年
・主要企業における多発性硬化症（MS）治療薬のグローバル販売量、2018年-2023年
・主要企業における多発性硬化症（MS）治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Bayer AG、 Bayhill Therapeutics、 Biogen Idec、 Cinnagen、 Daiichi Sankyo、 Eli Lilly、 Fast Forward Llc、 Antisense Therapeutics、 Apitope、 Five Prime Therapeutics、 Genmab、 Artielle Immunotherapeutics、 Genzyme、 Glaxosmithkline、 Gw Pharmaceuticals、 Innate Immunotherapeutics

*************************************************************

・調査・分析レポートの概要
多発性硬化症（MS）治療薬市場の定義
市場セグメント
世界の多発性硬化症（MS）治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の多発性硬化症（MS）治療薬市場規模
世界の多発性硬化症（MS）治療薬市場規模：2022年 VS 2029年
世界の多発性硬化症（MS）治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの多発性硬化症（MS）治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の多発性硬化症（MS）治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：コパキソン（グラチラマー酢酸塩）、ノバントロン（ミトキサントロン）、ジレニア（フィンゴリモド、Fty720）、オーバジオ（テリフルノミド）、テクフィデラ（フマル酸ジメチル）、フィラテグラスト（Sb683699、T-0047）、シポニモド（Baf312）、その他
多発性硬化症（MS）治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：RRMS、SPMS、PPMS、PRMS
多発性硬化症（MS）治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別多発性硬化症（MS）治療薬市場規模 2022年と2029年
地域別多発性硬化症（MS）治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Bayer AG、 Bayhill Therapeutics、 Biogen Idec、 Cinnagen、 Daiichi Sankyo、 Eli Lilly、 Fast Forward Llc、 Antisense Therapeutics、 Apitope、 Five Prime Therapeutics、 Genmab、 Artielle Immunotherapeutics、 Genzyme、 Glaxosmithkline、 Gw Pharmaceuticals、 Innate Immunotherapeutics
...

This report aims to provide a comprehensive presentation of the global market for Multiple Sclerosis (MS) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiple Sclerosis (MS) Drugs. This report contains market size and forecasts of Multiple Sclerosis (MS) Drugs in global, including the following market information:
Global Multiple Sclerosis (MS) Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Multiple Sclerosis (MS) Drugs Market Sales, 2018-2023, 2024-2029, (K Pcs)
Global top five Multiple Sclerosis (MS) Drugs companies in 2022 (%)
The global Multiple Sclerosis (MS) Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Copaxone (Glatiramer Acetate, Copolymer 1) Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Multiple Sclerosis (MS) Drugs include Bayer AG, Bayhill Therapeutics, Biogen Idec, Cinnagen, Daiichi Sankyo, Eli Lilly, Fast Forward Llc, Antisense Therapeutics and Apitope, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Multiple Sclerosis (MS) Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Multiple Sclerosis (MS) Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Multiple Sclerosis (MS) Drugs Market Segment Percentages, by Type, 2022 (%)
Copaxone (Glatiramer Acetate, Copolymer 1)
Novantrone (Mitoxantrone)
Gilenya (Fingolimod, Fty720)
Aubagio (Teriflunomide)
Tecfidera (Dimethyl Fumarate)
Firategrast (Sb683699, T-0047)
Siponimod (Baf312)
Others
Global Multiple Sclerosis (MS) Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Multiple Sclerosis (MS) Drugs Market Segment Percentages, by Application, 2022 (%)
RRMS
SPMS
PPMS
PRMS
Global Multiple Sclerosis (MS) Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Multiple Sclerosis (MS) Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Multiple Sclerosis (MS) Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Multiple Sclerosis (MS) Drugs revenues share in global market, 2022 (%)
Key companies Multiple Sclerosis (MS) Drugs sales in global market, 2018-2023 (Estimated), (K Pcs)
Key companies Multiple Sclerosis (MS) Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer AG
Bayhill Therapeutics
Biogen Idec
Cinnagen
Daiichi Sankyo
Eli Lilly
Fast Forward Llc
Antisense Therapeutics
Apitope
Five Prime Therapeutics
Genmab
Artielle Immunotherapeutics
Genzyme
Glaxosmithkline
Gw Pharmaceuticals
Innate Immunotherapeutics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Multiple Sclerosis (MS) Drugs, market overview.
Chapter 2: Global Multiple Sclerosis (MS) Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Multiple Sclerosis (MS) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Multiple Sclerosis (MS) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Multiple Sclerosis (MS) Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Multiple Sclerosis (MS) Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Multiple Sclerosis (MS) Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Multiple Sclerosis (MS) Drugs Overall Market Size
2.1 Global Multiple Sclerosis (MS) Drugs Market Size: 2022 VS 2029
2.2 Global Multiple Sclerosis (MS) Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Multiple Sclerosis (MS) Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Multiple Sclerosis (MS) Drugs Players in Global Market
3.2 Top Global Multiple Sclerosis (MS) Drugs Companies Ranked by Revenue
3.3 Global Multiple Sclerosis (MS) Drugs Revenue by Companies
3.4 Global Multiple Sclerosis (MS) Drugs Sales by Companies
3.5 Global Multiple Sclerosis (MS) Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Multiple Sclerosis (MS) Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Multiple Sclerosis (MS) Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Multiple Sclerosis (MS) Drugs Players in Global Market
3.8.1 List of Global Tier 1 Multiple Sclerosis (MS) Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Multiple Sclerosis (MS) Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Multiple Sclerosis (MS) Drugs Market Size Markets, 2022 & 2029
4.1.2 Copaxone (Glatiramer Acetate, Copolymer 1)
4.1.3 Novantrone (Mitoxantrone)
4.1.4 Gilenya (Fingolimod, Fty720)
4.1.5 Aubagio (Teriflunomide)
4.1.6 Tecfidera (Dimethyl Fumarate)
4.1.7 Firategrast (Sb683699, T-0047)
4.1.8 Siponimod (Baf312)
4.1.9 Others
4.2 By Type – Global Multiple Sclerosis (MS) Drugs Revenue & Forecasts
4.2.1 By Type – Global Multiple Sclerosis (MS) Drugs Revenue, 2018-2023
4.2.2 By Type – Global Multiple Sclerosis (MS) Drugs Revenue, 2024-2029
4.2.3 By Type – Global Multiple Sclerosis (MS) Drugs Revenue Market Share, 2018-2029
4.3 By Type – Global Multiple Sclerosis (MS) Drugs Sales & Forecasts
4.3.1 By Type – Global Multiple Sclerosis (MS) Drugs Sales, 2018-2023
4.3.2 By Type – Global Multiple Sclerosis (MS) Drugs Sales, 2024-2029
4.3.3 By Type – Global Multiple Sclerosis (MS) Drugs Sales Market Share, 2018-2029
4.4 By Type – Global Multiple Sclerosis (MS) Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Multiple Sclerosis (MS) Drugs Market Size, 2022 & 2029
5.1.2 RRMS
5.1.3 SPMS
5.1.4 PPMS
5.1.5 PRMS
5.2 By Application – Global Multiple Sclerosis (MS) Drugs Revenue & Forecasts
5.2.1 By Application – Global Multiple Sclerosis (MS) Drugs Revenue, 2018-2023
5.2.2 By Application – Global Multiple Sclerosis (MS) Drugs Revenue, 2024-2029
5.2.3 By Application – Global Multiple Sclerosis (MS) Drugs Revenue Market Share, 2018-2029
5.3 By Application – Global Multiple Sclerosis (MS) Drugs Sales & Forecasts
5.3.1 By Application – Global Multiple Sclerosis (MS) Drugs Sales, 2018-2023
5.3.2 By Application – Global Multiple Sclerosis (MS) Drugs Sales, 2024-2029
5.3.3 By Application – Global Multiple Sclerosis (MS) Drugs Sales Market Share, 2018-2029
5.4 By Application – Global Multiple Sclerosis (MS) Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Multiple Sclerosis (MS) Drugs Market Size, 2022 & 2029
6.2 By Region – Global Multiple Sclerosis (MS) Drugs Revenue & Forecasts
6.2.1 By Region – Global Multiple Sclerosis (MS) Drugs Revenue, 2018-2023
6.2.2 By Region – Global Multiple Sclerosis (MS) Drugs Revenue, 2024-2029
6.2.3 By Region – Global Multiple Sclerosis (MS) Drugs Revenue Market Share, 2018-2029
6.3 By Region – Global Multiple Sclerosis (MS) Drugs Sales & Forecasts
6.3.1 By Region – Global Multiple Sclerosis (MS) Drugs Sales, 2018-2023
6.3.2 By Region – Global Multiple Sclerosis (MS) Drugs Sales, 2024-2029
6.3.3 By Region – Global Multiple Sclerosis (MS) Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Multiple Sclerosis (MS) Drugs Revenue, 2018-2029
6.4.2 By Country – North America Multiple Sclerosis (MS) Drugs Sales, 2018-2029
6.4.3 US Multiple Sclerosis (MS) Drugs Market Size, 2018-2029
6.4.4 Canada Multiple Sclerosis (MS) Drugs Market Size, 2018-2029
6.4.5 Mexico Multiple Sclerosis (MS) Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Multiple Sclerosis (MS) Drugs Revenue, 2018-2029
6.5.2 By Country – Europe Multiple Sclerosis (MS) Drugs Sales, 2018-2029
6.5.3 Germany Multiple Sclerosis (MS) Drugs Market Size, 2018-2029
6.5.4 France Multiple Sclerosis (MS) Drugs Market Size, 2018-2029
6.5.5 U.K. Multiple Sclerosis (MS) Drugs Market Size, 2018-2029
6.5.6 Italy Multiple Sclerosis (MS) Drugs Market Size, 2018-2029
6.5.7 Russia Multiple Sclerosis (MS) Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Multiple Sclerosis (MS) Drugs Market Size, 2018-2029
6.5.9 Benelux Multiple Sclerosis (MS) Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Multiple Sclerosis (MS) Drugs Revenue, 2018-2029
6.6.2 By Region – Asia Multiple Sclerosis (MS) Drugs Sales, 2018-2029
6.6.3 China Multiple Sclerosis (MS) Drugs Market Size, 2018-2029
6.6.4 Japan Multiple Sclerosis (MS) Drugs Market Size, 2018-2029
6.6.5 South Korea Multiple Sclerosis (MS) Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Multiple Sclerosis (MS) Drugs Market Size, 2018-2029
6.6.7 India Multiple Sclerosis (MS) Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Multiple Sclerosis (MS) Drugs Revenue, 2018-2029
6.7.2 By Country – South America Multiple Sclerosis (MS) Drugs Sales, 2018-2029
6.7.3 Brazil Multiple Sclerosis (MS) Drugs Market Size, 2018-2029
6.7.4 Argentina Multiple Sclerosis (MS) Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Multiple Sclerosis (MS) Drugs Sales, 2018-2029
6.8.3 Turkey Multiple Sclerosis (MS) Drugs Market Size, 2018-2029
6.8.4 Israel Multiple Sclerosis (MS) Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Multiple Sclerosis (MS) Drugs Market Size, 2018-2029
6.8.6 UAE Multiple Sclerosis (MS) Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Bayer AG
7.1.1 Bayer AG Company Summary
7.1.2 Bayer AG Business Overview
7.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Major Product Offerings
7.1.4 Bayer AG Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Bayer AG Key News & Latest Developments
7.2 Bayhill Therapeutics
7.2.1 Bayhill Therapeutics Company Summary
7.2.2 Bayhill Therapeutics Business Overview
7.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Major Product Offerings
7.2.4 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Bayhill Therapeutics Key News & Latest Developments
7.3 Biogen Idec
7.3.1 Biogen Idec Company Summary
7.3.2 Biogen Idec Business Overview
7.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Major Product Offerings
7.3.4 Biogen Idec Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Biogen Idec Key News & Latest Developments
7.4 Cinnagen
7.4.1 Cinnagen Company Summary
7.4.2 Cinnagen Business Overview
7.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Major Product Offerings
7.4.4 Cinnagen Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Cinnagen Key News & Latest Developments
7.5 Daiichi Sankyo
7.5.1 Daiichi Sankyo Company Summary
7.5.2 Daiichi Sankyo Business Overview
7.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Major Product Offerings
7.5.4 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Daiichi Sankyo Key News & Latest Developments
7.6 Eli Lilly
7.6.1 Eli Lilly Company Summary
7.6.2 Eli Lilly Business Overview
7.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Major Product Offerings
7.6.4 Eli Lilly Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Eli Lilly Key News & Latest Developments
7.7 Fast Forward Llc
7.7.1 Fast Forward Llc Company Summary
7.7.2 Fast Forward Llc Business Overview
7.7.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Major Product Offerings
7.7.4 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Fast Forward Llc Key News & Latest Developments
7.8 Antisense Therapeutics
7.8.1 Antisense Therapeutics Company Summary
7.8.2 Antisense Therapeutics Business Overview
7.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Major Product Offerings
7.8.4 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Antisense Therapeutics Key News & Latest Developments
7.9 Apitope
7.9.1 Apitope Company Summary
7.9.2 Apitope Business Overview
7.9.3 Apitope Multiple Sclerosis (MS) Drugs Major Product Offerings
7.9.4 Apitope Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Apitope Key News & Latest Developments
7.10 Five Prime Therapeutics
7.10.1 Five Prime Therapeutics Company Summary
7.10.2 Five Prime Therapeutics Business Overview
7.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Major Product Offerings
7.10.4 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Five Prime Therapeutics Key News & Latest Developments
7.11 Genmab
7.11.1 Genmab Company Summary
7.11.2 Genmab Multiple Sclerosis (MS) Drugs Business Overview
7.11.3 Genmab Multiple Sclerosis (MS) Drugs Major Product Offerings
7.11.4 Genmab Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2018-2023)
7.11.5 Genmab Key News & Latest Developments
7.12 Artielle Immunotherapeutics
7.12.1 Artielle Immunotherapeutics Company Summary
7.12.2 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Business Overview
7.12.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Major Product Offerings
7.12.4 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2018-2023)
7.12.5 Artielle Immunotherapeutics Key News & Latest Developments
7.13 Genzyme
7.13.1 Genzyme Company Summary
7.13.2 Genzyme Multiple Sclerosis (MS) Drugs Business Overview
7.13.3 Genzyme Multiple Sclerosis (MS) Drugs Major Product Offerings
7.13.4 Genzyme Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2018-2023)
7.13.5 Genzyme Key News & Latest Developments
7.14 Glaxosmithkline
7.14.1 Glaxosmithkline Company Summary
7.14.2 Glaxosmithkline Business Overview
7.14.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Major Product Offerings
7.14.4 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2018-2023)
7.14.5 Glaxosmithkline Key News & Latest Developments
7.15 Gw Pharmaceuticals
7.15.1 Gw Pharmaceuticals Company Summary
7.15.2 Gw Pharmaceuticals Business Overview
7.15.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Major Product Offerings
7.15.4 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2018-2023)
7.15.5 Gw Pharmaceuticals Key News & Latest Developments
7.16 Innate Immunotherapeutics
7.16.1 Innate Immunotherapeutics Company Summary
7.16.2 Innate Immunotherapeutics Business Overview
7.16.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Major Product Offerings
7.16.4 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2018-2023)
7.16.5 Innate Immunotherapeutics Key News & Latest Developments
8 Global Multiple Sclerosis (MS) Drugs Production Capacity, Analysis
8.1 Global Multiple Sclerosis (MS) Drugs Production Capacity, 2018-2029
8.2 Multiple Sclerosis (MS) Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Multiple Sclerosis (MS) Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Multiple Sclerosis (MS) Drugs Supply Chain Analysis
10.1 Multiple Sclerosis (MS) Drugs Industry Value Chain
10.2 Multiple Sclerosis (MS) Drugs Upstream Market
10.3 Multiple Sclerosis (MS) Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Multiple Sclerosis (MS) Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 多発性硬化症（MS）治療薬のグローバル市場（2022年-2029年）：免疫調節剤、免疫抑制剤、インターフェロン
  • ナタリズマブ薬のグローバル市場展望 2023年-2029年：多発性硬化症、クローン病
  • タイサブリ薬の世界市場2022：多発性硬化症、クローン病
  • 自動注入装置のグローバル市場2023～2027：アナフィラキシー、多発性硬化症、関節リウマチ、糖尿病
  • 特殊医薬品のグローバル市場2023-2027：がん、多発性硬化症、炎症性疾患、感染症、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23JU5785 )"多発性硬化症（MS）治療薬のグローバル市場展望 2023年-2029年：コパキソン（グラチラマー酢酸塩）、ノバントロン（ミトキサントロン）、ジレニア（フィンゴリモド、Fty720）、オーバジオ（テリフルノミド）、テクフィデラ（フマル酸ジメチル）、フィラテグラスト（Sb683699、T-0047）、シポニモド（Baf312）、その他" (英文：Multiple Sclerosis (MS) Drugs Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。